Clinical trials
for patients
Learn about available clinical trials
-
September 15, 2025PamplonaIn recruitmentEarly phase
RIVER-81 Clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical efficacy of RVU120 in combination with venetoclax in participants with AML in whom previous treatment with venetoclax and a hypomethylating agent failed (RIVER-81).
The objectives of this study are to: ¿ Understand the appropriate dose of the study treatment (RVU120 venetoclax) for the subsequent study; ¿ Understand the effect of the study drug in reducing AML; ¿ Assess the tolerability of the study treatment and identify any potential side effects associated with the study drug; ¿ Perform pharmacokinetic (PK) testing to understand how the study treatment is metabolized and eliminated from the body; ¿ Assess how the study ... -
September 10, 2025PamplonaIn recruitment
-
September 8, 2025PamplonaIn recruitmentEarly phase
OMTX705-004 Study of OMTX705 in combination with regorafenib and tislelizumab in patients with advanced or metastatic colorectal cancer
The objective of this trial is to test whether a new drug, OMTX705, is safe and well tolerated when used in conjunction with two other existing drugs: regorafenib (Stivarga®) and tislelizumab (Tevimbra®), and to determine the most appropriate dose of these drugs for use in future trials and further clinical development of OMTX705. -
September 3, 2025Pamplona/MadridIn recruitmentEarly phase
ZN-c3-005 Phase II clinical trial to evaluate the efficacy and safety of ZN-c3 in patients with high-grade serous ovarian, fallopian tube or primary peritoneal ovarian cancer
The main objective of this study is: Part 1b: To determine the safety and tolerability of ZN-c3 in PROC subjects Part 2: To investigate the antitumor activity of ZN-c3 in PROC subjects -
September 1, 2025PamplonaIn recruitment
AC220-168 Phase III, double-blind, randomized, placebo-controlled clinical trial of quizartinib administered in combination with induction and consolidation chemotherapy and as maintenance therapy in adult patients with a diagnosis of
The purpose of this trial is to learn more about an investigational drug called QUIZARTINIB. An investigational drug is a drug that is not approved to treat your disease. It is being studied to see if your disease or medical condition improves while you are receiving it and if it is safe for people who have the same disease as you. -
August 27, 2025Pamplona/MadridIn recruitment
-
August 25, 2025PamplonaIn recruitment
PLATFORMPACAN1001 Ensayo clínico para la continuación del tratamiento del estudio y el seguimiento de la seguridad.
Clinical trial for continuation of study treatment and safety monitoring. -
August 18, 2025Pamplona/MadridIn recruitment
J2N-MC-JZNZ Clinical trial to determine the dose of Pirtobrutinib in adults with immune thrombocytopenia
The main objective is to ensure the safety and efficacy of Pirtobrutinib in patients with immune thrombocytopenia, and to select the doses for part 2 of this study. -
August 7, 2025Pamplona/MadridIn recruitmentEarly phase
ASTX030-01 Study of ASTX030 (cedazuridine in combination with azacitidine) in MDS, CMML or AML
The purpose of this study is to analyze the levels of the experimental drug ASTX030 in their blood, to assess the safety and tolerability of the drugs, and to find out how the participants respond to the drug. -
August 5, 2025Pamplona/MadridIn recruitmentEarly phase
CYTB323K12201 Trial of rapcabtagene autoleucel versus rituximab in participants with severe refractory diffuse diffuse cutaneous systemic sclerosis
The purpose of this study is to find out if YTB323 is safe and effective (if it can help) in people with severe refractory ESCD.